We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
TIDMEVG
RNS Number : 3213R
Evgen Pharma PLC
05 March 2021
5 March 2021
Evgen Pharma plc
("Evgen Pharma" or "the Company")
Director dealing
Evgen Pharma plc (AIM: EVG), a clinical stage drug development company, has been notified that Richard Moulson, Chief Financial Officer of the Company, has purchased 3,787 ordinary shares of 0.25 pence each in the capital of the Company ("Ordinary Shares") at a purchase price of 8 pence per Ordinary Share, as part of the Open Offer in the recent Fundraise. Following this purchase, Richard Moulson holds a total of 45,454 Ordinary Shares, representing approximately 0.02 per cent. of the Company's issued share capital.
Enquiries:
Evgen Pharma plc Via Walbrook Barry Clare, Chairman Dr Huw Jones, CEO Richard Moulson, CFO finnCap Geoff Nash / Teddy Whiley (Corporate Finance) Alice Lane / Sunila de Silva (ECM) www.finncap.com +44 (0) 20 7220 0500 Walbrook PR +44 (0)20 7933 87870 or evgen@walbrookpr.com Paul McManus/ Anna Dunphy +44 (0)7980 541 893 / +44 (0)7876 741 001
About Evgen Pharma plc
Evgen Pharma is a clinical stage drug development company developing sulforaphane based medicines for the treatment of multiple diseases. The Company's core technology is Sulforadex(R), a method for synthesising and stabilising the naturally occurring compound sulforaphane and novel proprietary analogues based on sulforaphane. The lead product, SFX-01, is a patented composition of synthetic sulforaphane and alpha-cyclodextrin.
Clinical data from the Company's open-label Phase II STEM trial has shown that SFX-01 can halt the growth of progressing tumours in patients with oestrogen-positive (ER+) metastatic breast cancer, and in some cases significantly shrink the tumour, whilst causing very few side effects.
The Company commenced operations in January 2008 and has its headquarters at The Colony, Wilmslow, Cheshire, and its registered office is at the Liverpool Science Park, Liverpool. It joined the AIM market of the London Stock Exchange in October 2015 and trades under the ticker symbol EVG.
For further information, please visit: www.evgen.com
Accordingly, the Company makes the following announcement and notification in accordance with the EU Market Abuse Regulation (No 596/2014):
1. Details of Persons Discharging Managerial Responsibilities "PDMR" / person closely associated with them ('PCA') ================================================================================== a) Name Richard Moulson ================================ ================================================ 2. Reason for notification ================================================================================== b) Position / status CFO ================================ ================================================ c) Initial notification / amendment Initial Notification ================================ ================================================ 3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor ================================================================================== b) Name Evgen Pharma plc ================================ ================================================ c) LEI 213800NO3E6TSTQO8K20 ================================ ================================================ 4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ================================================================================== a) Description of the financial ordinary shares of 0.25p each instrument Identification code GB00BSVYN304 ================================ ================================================ b) Nature of the transaction Acquisition of shares pursuant to the Open Offer ================================ ================================================ c) Price(s) and volume(s) Price(s) Volume(s) GBP0.08 3,787 ---------- ================================ ================================================ d) Aggregated information As above Aggregated volume Price ================================ ================================================ e) Date of the transaction 3 March 2021 ================================ ================================================ f) Place of the transaction London Stock Exchange, AIM Market (XLON) ================================ ================================================
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDKPBDCBKKPNK
(END) Dow Jones Newswires
March 05, 2021 04:17 ET (09:17 GMT)
1 Year Evgen Pharma Chart |
1 Month Evgen Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions